AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04585594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
Description: The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
Study NCT01631578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of an autologous mitochondria to the oocyte.
Description: In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
Study NCT03260374 — intervention group
Intervention type: DEVICE
Intervention: Electric compound action potential
Description: The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
Study NCT03260374 — intervention group
Intervention type: DEVICE
Intervention: electric stapedial reflex threshold
Description: electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
Study NCT03260374 — intervention group
Intervention type: DEVICE
Intervention: electric auditory brain stem response
Description: For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
Study NCT04122911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: pharmacological
Study NCT03273452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
Study NCT02687971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine
Description: Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
Study NCT02687971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
Study NCT03438279 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03922529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MACRO-I
Description: MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
Study NCT03922529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
Study NCT04131322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amgevita 40Mg Solution for Injection
Description: Adalimumab 40Mg Solution for Injection
Study NCT04131322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUMIRA 40Mg Solution for Injection
Description: Adalimumab 40Mg Solution for Injection
Study NCT03004261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor derived cytomegalovirus specific T lymphocytes
Description: donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
Study NCT03004261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet
Description: Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
Study NCT03004261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
Study NCT01631578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of an autologous mitochondria to the oocyte.
Description: In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
Study NCT03295578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake.
Study NCT03295578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic feedback
Description: The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
Study NCT03295578 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous glucose monitoring device
Description: This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
Study NCT03295578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring device
Description: This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
Study NCT01291173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489-30mg capsules taken once daily for up to 11 weeks
Study NCT01291173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489 50mg capsules taken once-daily for up to 11 weeks
Study NCT01291173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate (SPD489)
Description: SPD489 70mg capsule taken once-daily for up to 11 weeks
Study NCT01291173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken once daily for up to 11 weeks
Study NCT03507894 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multimodal Exercise Rehabilitation Program
Description: Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
Study NCT02073994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
Study NCT00912964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching mirabegron placebo tablets.
Study NCT01421836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP-guided stent insertion
Description: ERCP guided stent insertion for malignant biliary obstruction
Study NCT01421836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided stent insertion
Description: EUS-guided stent insertion for malignant biliary obstruction
Study NCT03433794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol 101 Plus (TM)
Description: It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
Study NCT03433794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol 101 Plus (TM)
Description: It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
Study NCT03433794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster
Description: Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
Study NCT03433794 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lilly for Better Health
Description: This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
Study NCT01035463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic stem cell transplant
Study NCT01035463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT01035463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01035463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01035463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01035463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01035463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02526563 — intervention group
Intervention type: PROCEDURE
Intervention: ropivicaine
Description: Blood draws to measure serum ropivicaine
Study NCT01412450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nitinol stent
Description: implantation of one Protégé EverFlex stent
Study NCT02022761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate
Description: 40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Study NCT02022761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Laninamivir octanoate
Description: 40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
Study NCT00964041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg by mouth weekly, one hour before assessments, for eight weeks.
Study NCT00964041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
Study NCT01250184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Twelve sessions (3 per week)
Study NCT01250184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
Study NCT01250184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine injection + physical therapy
Description: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
Study NCT04654611 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: preservative free tafluprost 0.0015%
Description: preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
Study NCT03091517 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GlycoLeap
Description: GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback.
Study NCT03639636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non surgical and surgical periodontal therapy
Description: scaling and root planing periodontal flap surgery
Study NCT02604602 — intervention group
Intervention type: OTHER
Intervention: blood exam
Description: laboratory test
Study NCT04277663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310+IBI308
Description: In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
Study NCT04277663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
Study NCT04277663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose recombinant interferon a-2B
Description: In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
Study NCT01904474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next.Step - e-therapeutic intervention program
Study NCT01904474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment protocol
Study NCT01922947 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivational Interviewing w/Social Network Counseling
Description: This is the active arm of the study.
Study NCT01922947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Condition
Description: 20-minute health counseling
Study NCT02138409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
Study NCT02138409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sublingual Spray (PSS)
Description: Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
Study NCT01880294 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
Study NCT01581034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PADMA 28
Description: PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
Study NCT01581034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
Study NCT01891799 — intervention group
Intervention type: OTHER
Intervention: Option B+
Description: * Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women
Study NCT01271712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
Study NCT01271712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily (od), 3 weeks on/1 week off. Route of administration: oral
Study NCT01271712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Study NCT01271712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Study NCT01059682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: Dalcetrapib 600 mg orally once daily
Study NCT01059682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study NCT02580123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention taught by trained educators
Study NCT01407835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
Description: Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study NCT03086291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days